Hims & Hers Health
Corporate brand
UnclaimedA consumer-focused telehealth company providing online consultations, prescription medicines, over-the-counter products, and personal care through subscription-based digital health services.
Last updated October 16, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Hims & Hers Health, Inc., commonly branded as hims, is an American telehealth and digital health company headquartered in San Francisco. The company connects consumers with licensed healthcare professionals through online consultations and sells prescription medicines, over-the-counter treatments, personal care products, and related wellness offerings through a direct-to-consumer platform. Its services are generally organized around health categories rather than conventional medical specialties, with offerings spanning men's sexual health, hair loss, dermatology, women's health, mental health, primary care, and weight management. The business began in November 2017 as Hims, Inc., a venture associated with Atomic Labs, the San Francisco venture studio co-founded by Andrew Dudum and Jack Abraham. Its initial proposition was to make treatments for conditions such as erectile dysfunction and male-pattern hair loss easier to access, while presenting them through a consumer brand emphasizing convenience, discretion, and straightforward digital ordering. The company primarily used generic prescription medicines and personal-care products, supported by online medical assessments and clinician review. Early funding included a reported $7 million seed round from investors including Forerunner Ventures and Thrive Capital. In 2018, the company introduced Hers, a related brand aimed at women's health. Hers expanded the platform beyond men's treatments into birth control, skincare, hair regrowth, and other services. Hims later adopted a combined corporate identity, retaining distinct consumer-facing positioning for the two brands while broadening the platform's addressable market. The company raised $100 million in Series C financing in January 2019 and launched in the United Kingdom later that year. The COVID-19 pandemic accelerated the company's move into behavioral healthcare. In 2020, Hims & Hers introduced free anonymous group therapy sessions and subsequently added online psychiatry consultations and individual teletherapy. The company also expanded its clinical and product infrastructure through acquisitions, including the United Kingdom-based Honest Health in 2021 and teledermatology company Apostrophe, operated by YoDerm, Inc., in the same year. Hims & Hers became a public company through a merger with Oaktree Acquisition Corp. The transaction closed on January 20, 2021, at a reported valuation of approximately $1.6 billion, and the company's shares began trading on the New York Stock Exchange under HIMS the following day. The transaction supplied approximately $280 million in reported proceeds, including private placement financing. During 2024 and 2025, weight management became a major strategic and regulatory focus. Hims & Hers began offering access to compounded injectable semaglutide during a period when branded semaglutide products were in shortage, and acquired MedisourceRx, a licensed 503B compounding outsourcing facility, in September 2024. The company's February 2025 Super Bowl advertisement, “Sick of the System,” promoted its weight-loss offering and generated criticism concerning the presentation of compounded medicines and the disclosure of risks. The company later announced a collaboration with Novo Nordisk to make branded Wegovy available through its platform, but Novo Nordisk terminated that arrangement in June 2025 while criticizing Hims & Hers' continued sale and promotion of compounded semaglutide. The business has continued international expansion through its acquisition of ZAVA in 2025 and its announced agreement to acquire Eucalyptus Health in 2026. At the same time, its compounded-drug advertising, subscription practices, and weight-management communications have drawn regulatory and legal scrutiny. Hims & Hers therefore occupies a position between consumer health, online clinical services, pharmacy distribution, and digital subscription commerce. Its brand promise centers on accessible, private, and c…
History
Hims & Hers Health originated in San Francisco in November 2017 as Hims, Inc., founded by Andrew Dudum, Jack Abraham, and Hilary Coles in association with Atomic Labs. The initial business addressed men's health through an online, direct-to-consumer model. Customers could complete health questionnaires or consultations online, receive review by licensed clinicians where appropriate, and obtain prescription or non-prescription treatments for conditions including erectile dysfunction and hair loss. The company also sold skincare and other personal-care products. Its branding sought to reduce the embarrassment and friction associated with seeking treatment for intimate conditions. The company raised an early seed round reported at $7 million and expanded its proposition in 2018 with the launch of Hers. Hers targeted women's health, including birth control, skincare, and hair-regrowth products. This two-brand structure allowed the business to market differently to men and women while using a shared technology, clinical, and fulfillment infrastructure. In January 2019, Hims raised a reported $100 million Series C round at a reported pre-money valuation of $1 billion. Later that year, it entered the United Kingdom, its first international market. In 2020, the COVID-19 pandemic increased demand for remote healthcare and encouraged the company to broaden beyond its original product categories. Hims & Hers introduced free anonymous group therapy and later added psychiatry consultations and individual teletherapy. The move made behavioral health a significant part of the platform and reinforced its positioning as a consumer health company rather than only an online pharmacy. The company entered public markets through a merger with Oaktree Acquisition Corp., a special-purpose acquisition company sponsored by Oaktree Capital Management. The transaction closed on January 20, 2021, at a reported valuation of $1.6 billion. Shares began trading on the New York Stock Exchange on January 21 under HIMS. The transaction reportedly generated about $280 million in proceeds, including a private placement involving investors such as Franklin Templeton. In June 2021, Hims & Hers acquired London-based Honest Health, and in July it acquired teledermatology company Apostrophe, also known as YoDerm, Inc., for potential consideration of up to $200 million. Apostrophe was later shut down in 2025. Weight management became a central strategic area in 2024. During a shortage of branded semaglutide medicines, Hims & Hers began offering access to compounded injectable semaglutide. In September 2024, the company acquired MedisourceRx, a licensed 503B compounding outsourcing facility, giving it greater involvement in the supply chain for compounded medicines. This strategy exposed the company to heightened scrutiny because compounded drugs are not equivalent to FDA-approved products in regulatory status, labeling, or review. In February 2025, the company aired “Sick of the System,” a 60-second advertisement during Super Bowl LIX. The commercial promoted the company's GLP-1 weight-loss services and was criticized by public health experts, industry organizations, and members of Congress for emphasizing access while allegedly failing to provide adequate information about potential risks. Senators Dick Durbin and Roger Marshall sent a letter to the FDA requesting enforcement action. In April 2025, Hims & Hers announced a collaboration with Novo Nordisk to make branded Wegovy available through the Hims & Hers platform as part of a membership offering. Novo Nordisk terminated the arrangement on June 23, 2025, alleging deceptive promotion and the sale of unauthorized or illegitimate versions of Wegovy. The announcement was followed by a sharp decline in the company's share price and securities class-action litigation alleging that investors had not been adequately informed about risks to the partnership. Hims & Hers continued expanding internationally with its June 2025 agreement to acquire ZAVA, a London-based European digital health company serving the United Kingdom, Germany, France, and Ireland. Later reporting described an FTC investigation into advertising and subscription-cancellation practices. In September 2025, the FDA issued a warning concerning claims that compounded products contained the same active ingredient as FDA-approved Ozempic and Wegovy products. In February 2026, Hims & Hers briefly introduced a compounded oral semaglutide pill, withdrew it shortly afterward following threatened patent litigation from Novo Nordisk, and then faced a formal infringement suit. On February 19, 2026, the company announced an agreement to acquire Australian digital health company Eucalyptus Health, operator of the Juniper, Pilot, and Kin brands. The company's history reflects the rapid growth of consumer telehealth alongside persistent questions about clinical oversight, pharmaceutical compounding, advertising standards, and sustainable international expansion.
- 2026
Australian expansion proposed
[1]The company announces an agreement to acquire Eucalyptus Health and its Juniper, Pilot, and Kin brands.
- 2025
Novo Nordisk collaboration ends amid dispute
[1]A planned Wegovy collaboration is terminated while the companies dispute promotion and compounded semaglutide.
- 2024
Weight-management expansion
[1]Hims & Hers adds compounded injectable semaglutide access and acquires MedisourceRx.
- 2021
Public listing and acquisitions
[1]The company completes its SPAC merger, begins NYSE trading, and acquires Honest Health and Apostrophe.
- 2020
Mental health expansion
[1]The platform introduces anonymous group therapy and expands into psychiatry and individual teletherapy.
- 2019
Series C financing and United Kingdom launch
[1]Hims raises a reported $100 million Series C round and begins international operations in the United Kingdom.
- 2018
Hers launches
[1]The company introduces Hers for women's health, adding products and services such as birth control, skincare, and hair regrowth.
- 2017
Hims is founded
[1]Andrew Dudum, Jack Abraham, and Hilary Coles establish Hims, Inc. in San Francisco in association with Atomic Labs.
Products and positioning
A consumer-oriented digital health platform emphasizing convenience, privacy, subscription access, and simplified online treatment pathways.
Men's health · 2017
Hims men's health
The original Hims proposition centers on online access to treatments for erectile dysfunction, hair loss, and related personal-care needs. The offering combines clinician consultations, prescription medicines where clinically appropriate, generic treatment options, and non-prescription products delivered through a consumer subscription and fulfillment model.
Women's health · 2018
Hers women's health
Hers extends the platform into women's health with services and products associated with birth control, skincare, hair regrowth, and other conditions. It is positioned as a convenient online route to clinical review and treatment rather than as a conventional clinic or retail pharmacy.
Behavioral health · 2020
Mental health services
The company provides digital behavioral-health services that have included anonymous group therapy, psychiatry consultations, and individual teletherapy. These services broadened Hims & Hers from medication access into ongoing mental-health support and clinician-led care.
Teledermatology
Apostrophe
Apostrophe was a teledermatology platform acquired by Hims & Hers in 2021. It provided online dermatology consultations and treatment pathways, complementing Hims & Hers' existing skincare and hair-loss categories. The platform was shut down in 2025.
Weight management · 2024
Weight management
Hims & Hers introduced a weight-loss specialty that included access to compounded injectable semaglutide during a period of branded-drug shortage. The category became a major source of regulatory, advertising, pharmaceutical, and litigation attention because compounded medicines are not FDA-approved substitutes for branded products.
Controversies
2026
Semaglutide patent dispute
After Hims & Hers briefly offered a compounded oral semaglutide product, Novo Nordisk announced its intention to sue and later filed a patent-infringement action. Hims & Hers withdrew the product from its platform.
2026
Securities class action lawsuit filed against Hims & Hers Health
A securities class action lawsuit was filed against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026. The complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts, including that the company shared consumers' health information with third-party advertising platforms and charged consumers for prescriptions almost immediately after they submitted an intake form despite telling consumers they would be able to consult with a medical provider. Wolf Haldenstein Adler Freeman & Herz LLP announced the action, with the lead-plaintiff deadline set for November 2, 2026. The suit follows a July 29, 2026 enforcement action by the FTC, the People of the State of California and the Utah Division of Consumer Protection alleging deceptive prescription billing, difficult subscription cancellation and misleading privacy practices, after which Hims & Hers stock fell 14.73% to close at $25.00 per share.
2025
GLP-1 advertising controversy
Hims & Hers faced criticism over its Super Bowl promotion of compounded semaglutide and allegations that its presentation did not sufficiently disclose product risks or the distinction between compounded and FDA-approved medicines.
2025
Novo Nordisk partnership termination
Novo Nordisk ended its Wegovy collaboration with Hims & Hers, alleging deceptive promotion and sales of illegitimate or unauthorized versions of Wegovy. Securities litigation followed the announcement.
2025
Advertising and subscription-practice scrutiny
The company was reported to be under FTC investigation concerning advertising claims and subscription cancellation practices. The FDA separately warned about claims regarding the active ingredient in compounded products.
Marketing campaigns
- 2025Sick of the System
United States
A 60-second Super Bowl LIX advertisement presented Hims & Hers' GLP-1 weight-management offering as an alternative to perceived shortcomings in the healthcare system. Critics argued that the commercial did not adequately communicate the risks and regulatory distinctions associated with compounded semaglutide. The campaign generated substantial public, industry, congressional, and regulatory criticism.
Outcome. The campaign generated substantial public, industry, congressional, and regulatory criticism.
Brand decisions
2026
Withdraw compounded oral semaglutideProduct launchBackground
Hims & Hers introduced a compounded oral semaglutide product while Novo Nordisk's branded oral Wegovy was entering the market.
Action taken
The company withdrew the compounded oral pill after Novo Nordisk threatened patent litigation.
Aftermath
Novo Nordisk subsequently filed a patent-infringement lawsuit in federal court.
- Novo Nordisk — Novo Nordisk announced and then filed patent litigation concerning semaglutide-related intellectual property.
2025
Collaborate with Novo Nordisk on branded WegovyStrategyBackground
The company attempted to combine its consumer platform and membership model with access to a branded GLP-1 medicine.
Action taken
Hims & Hers announced that branded Wegovy would be offered through its platform as part of a monthly membership.
Aftermath
Novo Nordisk terminated the collaboration in June 2025 amid disputes over promotion and compounded semaglutide.
- Novo Nordisk — Novo Nordisk terminated the collaboration and criticized the promotion and sale of compounded products.
2024
Enter compounded GLP-1 weight managementStrategyBackground
Shortages of branded semaglutide products created a market opportunity for legally permitted compounding under applicable pharmacy rules.
Action taken
Hims & Hers began offering access to compounded injectable semaglutide and acquired MedisourceRx to strengthen supply-chain control.
Aftermath
Weight management became strategically important but also triggered intense advertising, regulatory, and pharmaceutical-industry scrutiny.
2021
Acquire Honest Health and ApostropheM&ABackground
The company sought international growth and deeper capabilities in digital dermatology.
Action taken
Hims & Hers acquired Honest Health in the United Kingdom and teledermatology company Apostrophe.
Aftermath
The acquisitions broadened geographic reach and clinical categories, although Apostrophe was later shut down.
2020
Expand into mental healthcareStrategyBackground
The COVID-19 pandemic increased demand for remote healthcare and created an opportunity to extend the platform beyond men's and women's medication categories.
Action taken
Hims & Hers launched anonymous group therapy and later added psychiatry and individual teletherapy services.
Aftermath
The company became a broader digital health platform with behavioral healthcare as a significant service category.
Recent events
- Unconfirmed
Reported
Hims & Hers rebrands Juniper into the Hers brand identity in Australia[5]
As part of the Australian launch, Hims & Hers replaced the legacy Juniper entity—Eucalyptus's established women's health venture operated in Australia since 2021—with the Hers global brand identity, while retaining Australian-licensed physicians and continuity of local clinical oversight for existing subscribers.
- Unconfirmed
Reported
Hims & Hers launches women's health platform Hers in Australia[5]
Hims & Hers Health has officially introduced its women-focused telehealth platform Hers to the Australian healthcare market, transforming the Juniper venture into the fully integrated Hers platform. The transitioned platform introduces expanded diagnostic and treatment categories including perimenopause and menopause support, advanced hair restoration formulations, and comprehensive weight management programs, following the company's $1.15 billion acquisition of Eucalyptus earlier in the year.
- Unconfirmed
Reported
Securities class action lawsuit filed against Hims & Hers Health[3]
A securities class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026. The complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts, including that the company shared consumers' health information with third-party advertising platforms and charged consumers for prescriptions almost immediately after they submitted an intake form despite telling consumers they would be able to consult with a medical provider. Wolf Haldenstein Adler Freeman & Herz LLP announced the action, with the lead-plaintiff deadline set for November 2, 2026. The suit follows a July 29, 2026 enforcement action by the FTC, the People of the State of California and the Utah Division of Consumer Protection alleging deceptive prescription billing, difficult subscription cancellation and misleading privacy practices, after which Hims & Hers stock fell 14.73% to close at $25.00 per share.
Reported
FTC sues Hims & Hers over privacy and billing practices[4]
The U.S. Federal Trade Commission, joined by California and Utah, sued Hims & Hers in federal court, alleging that the company shared consumers’ sensitive health information with advertising platforms without consent and charged some customers for prescriptions or recurring subscriptions without adequate disclosure or approval. The allegations have not been determined by the court.
Reported
Truework and Hims & Hers partner to provide COVID-19 testing access[6]
Truework announced a partnership with Hims & Hers to give employees of Truework partner companies access to COVID-19 testing through the Hims & Hers platform.
Reported
Hims and Hers launch group therapy services[7]
Hims launched group therapy services through its Hims and Hers brands as part of an initial expansion into mental health services. The offerings include anonymized group therapy and guided meditation sessions.
Sources7 sources
- 1Hims & Hers Healthen.wikipedia.org
- 2Hims & Hers Health official websitehims.com
- 3Shareholders Who Lost Money in Shares of Acquired Hims & Hers Health, Inc. (NYSE: HIMS) Should Contact Wolf Haldenstein Immediatelyprnewswire.com
- 4FTC Sues Hims & Hers Over Health Privacy and Billing Practicesneurologyadvisor.com
- 5Hims & Hers 将澳大利亚 Juniper 品牌重塑为 Hersibtimes.com.au
- 6Truework 与 Hims & Hers 合作提供新冠检测服务prnewswire.com
- 7Hims 和 Hers 推出团体治疗服务techcrunch.com
Cite this profile: Cite the canonical profile. /brand-wiki/hims-and-hers-health · Editorial policy · How profiles are compiled